IL310176A - Deuterated compounds - Google Patents

Deuterated compounds

Info

Publication number
IL310176A
IL310176A IL310176A IL31017624A IL310176A IL 310176 A IL310176 A IL 310176A IL 310176 A IL310176 A IL 310176A IL 31017624 A IL31017624 A IL 31017624A IL 310176 A IL310176 A IL 310176A
Authority
IL
Israel
Prior art keywords
deuterated compounds
deuterated
compounds
Prior art date
Application number
IL310176A
Other languages
English (en)
Hebrew (he)
Original Assignee
Alebund Pharmaceuticals Hong Kong Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alebund Pharmaceuticals Hong Kong Ltd filed Critical Alebund Pharmaceuticals Hong Kong Ltd
Publication of IL310176A publication Critical patent/IL310176A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/422Oxazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002Heterocyclic compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
IL310176A 2021-08-13 2022-08-09 Deuterated compounds IL310176A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2021112521 2021-08-13
CN2022106648 2022-07-20
PCT/CN2022/111089 WO2023016440A1 (en) 2021-08-13 2022-08-09 Deuterated compounds

Publications (1)

Publication Number Publication Date
IL310176A true IL310176A (en) 2024-03-01

Family

ID=85199822

Family Applications (1)

Application Number Title Priority Date Filing Date
IL310176A IL310176A (en) 2021-08-13 2022-08-09 Deuterated compounds

Country Status (11)

Country Link
US (1) US20240270731A1 (https=)
EP (1) EP4384507A4 (https=)
JP (1) JP2024532807A (https=)
KR (1) KR20240047401A (https=)
CN (1) CN116848095B (https=)
AR (1) AR126778A1 (https=)
CA (1) CA3227149A1 (https=)
IL (1) IL310176A (https=)
MX (1) MX2024001889A (https=)
TW (1) TW202320762A (https=)
WO (1) WO2023016440A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118480034B (zh) * 2023-02-13 2025-02-11 礼邦医药(香港)有限公司 氘代化合物的晶型或盐
TW202547458A (zh) * 2024-03-26 2025-12-16 香港商禮邦醫藥(香港)有限公司 用於治療體染色體顯性多囊性腎病之方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60211891T2 (de) * 2001-05-15 2007-05-24 F. Hoffmann-La Roche Ag Carbonsäure-substituierte oxazol-derivate zur verwendung als ppar-alpha und -gamma aktivatoren zur behandlung von diabetes
US7262303B2 (en) * 2003-09-29 2007-08-28 Hoffman-La Roche Inc. Process for the production of chiral propionic acid derivatives
JP7618384B2 (ja) * 2017-02-21 2025-01-21 ジェンフィ Pparアゴニストとfxrアゴニストとの組合せ
CN109265380A (zh) * 2017-10-18 2019-01-25 深圳市塔吉瑞生物医药有限公司 取代的丙-2-烯-1-酮化合物及其药物组合物
WO2020156683A1 (en) * 2019-02-01 2020-08-06 F. Hoffmann-La Roche Ag Aleglitazar for use in the treatment or prevention of major adverse cardiac events
CN112209896B (zh) * 2019-07-10 2023-05-16 苏州泽璟生物制药股份有限公司 噻唑烷二酮衍生物以及包含其的药物组合物
CN118480034B (zh) * 2023-02-13 2025-02-11 礼邦医药(香港)有限公司 氘代化合物的晶型或盐

Also Published As

Publication number Publication date
TW202320762A (zh) 2023-06-01
CA3227149A1 (en) 2023-02-16
AR126778A1 (es) 2023-11-15
US20240270731A1 (en) 2024-08-15
EP4384507A4 (en) 2025-06-18
CN116848095A (zh) 2023-10-03
EP4384507A1 (en) 2024-06-19
JP2024532807A (ja) 2024-09-10
WO2023016440A1 (en) 2023-02-16
AU2022327461A1 (en) 2024-02-01
KR20240047401A (ko) 2024-04-12
CN116848095B (zh) 2024-05-24
MX2024001889A (es) 2024-02-29

Similar Documents

Publication Publication Date Title
EP4452937A4 (en) CONNECTIONS
IL311050A (en) Deuterated empathogens
IL310176A (en) Deuterated compounds
GB202016614D0 (en) Compounds
GB202013558D0 (en) GRP52 Modularor compounds
GB202001564D0 (en) Compounds
GB202103981D0 (en) Deuterated compounds
GB202103008D0 (en) Compounds
GB202020047D0 (en) Compounds
GB202017406D0 (en) Compounds
GB202016977D0 (en) Compounds
GB202014944D0 (en) Compounds
GB202011812D0 (en) Compounds
GB202011811D0 (en) Compounds
GB202201331D0 (en) Deuterated compounds
ES3063655T3 (en) Compounds
GB202103012D0 (en) Compounds
GB202102709D0 (en) Compounds
GB202100645D0 (en) Compounds
GB202020370D0 (en) Compounds
GB202019428D0 (en) Compounds
GB202019429D0 (en) Compounds
GB202019427D0 (en) Compounds
GB202018034D0 (en) Compounds
GB202017630D0 (en) Compounds